| 000 | 02599 a2200817 4500 | ||
|---|---|---|---|
| 005 | 20250513093144.0 | ||
| 264 | 0 | _c19960909 | |
| 008 | 199609s 0 0 eng d | ||
| 022 | _a0006-4971 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBacigalupo, A | |
| 245 | 0 | 0 |
_aThiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. _h[electronic resource] |
| 260 |
_bBlood _cJul 1996 |
||
| 300 |
_a353-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aActuarial Analysis |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Marrow _xdrug effects |
| 650 | 0 | 4 |
_aBone Marrow Diseases _xchemically induced |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xetiology |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadverse effects |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aHematopoietic Stem Cells _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfections _xetiology |
| 650 | 0 | 4 |
_aLeukapheresis _xadverse effects |
| 650 | 0 | 4 |
_aLeukemia _xblood |
| 650 | 0 | 4 |
_aLymphoma _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xblood |
| 650 | 0 | 4 |
_aMultiple Organ Failure _xetiology |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xblood |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xblood |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThiotepa _xadministration & dosage |
| 650 | 0 | 4 | _aTissue Donors |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aVan Lint, M T | |
| 700 | 1 | _aValbonesi, M | |
| 700 | 1 | _aLercari, G | |
| 700 | 1 | _aCarlier, P | |
| 700 | 1 | _aLamparelli, T | |
| 700 | 1 | _aGualandi, F | |
| 700 | 1 | _aOcchini, D | |
| 700 | 1 | _aBregante, S | |
| 700 | 1 | _aValeriani, A | |
| 700 | 1 | _aPiaggio, G | |
| 700 | 1 | _aPitto, A | |
| 700 | 1 | _aBenvenuto, F | |
| 700 | 1 | _aFigari, O | |
| 700 | 1 | _aDe Stefano, G | |
| 700 | 1 | _aCaimo, A | |
| 700 | 1 | _aSessarego, M | |
| 773 | 0 |
_tBlood _gvol. 88 _gno. 1 _gp. 353-7 |
|
| 999 |
_c8701438 _d8701438 |
||